Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia

Leukemia - United Kingdom
doi 10.1038/leu.2014.245
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Clinical and Prognostic Significance of E1a2 BCR-ABL1 Transcript Subtype in Chronic Myeloid Leukemia

Blood Cancer Journal
OncologyHematology
2017English

Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia

Molecular Therapy - Nucleic Acids
Drug DiscoveryMolecular Medicine
2017English

The Benefit of Quality Control Charts (QCC) for Routine Quantitative BCR-ABL1 Monitoring in Chronic Myeloid Leukemia

PLoS ONE
Multidisciplinary
2018English

Requirement of SRC Kinases Lyn, HCK and FGR for BCR-ABL1-induced B-Lymphoblastic Leukemia but Not Chronic Myeloid Leukemia

Nature Genetics
Genetics
2004English

Combined Inhibition of MDM2 and BCR-Abl Tyrosine Kinase Targets Chronic Myeloid Leukemia Stem/Progenitor Cells in a Murine Model

Haematologica
Hematology
2019English

The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients With Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2018English

A Novel BCR-ABL1 Fusion Gene With Genetic Heterogeneity Indicates a Good Prognosis in a Chronic Myeloid Leukemia Case

Molecular Cytogenetics
BiochemistryMolecular MedicineGeneticsMolecular Biology
2017English

MPT0B169, a New Antitubulin Agent, Inhibits BCR-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells

PLoS ONE
Multidisciplinary
2016English

Differential Genomics and Transcriptomics Between Tyrosine Kinase Inhibitor-Sensitive and -Resistant BCR-ABL-dependent Chronic Myeloid Leukemia

Oncotarget
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy